A notable example is ARQ092 (Miransertib), a selective allosteric inhibitor of AKT1, which has shown promise in clinical trials for patients with PI3K/Akt-driven tumors or Proteus syndrome [46]. The gene discussed is AKT1; the disease is Proteus syndrome.